Boston Scientific Corp (BSX)

NYSE
Currency in USD
102.36
+1.06(+1.05%)
Closed·
Pre Market
102.360.00(0.00%)
·
BSX Scorecard
Full Analysis
Net income is expected to grow this year
BSX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
100.90102.40
52 wk Range
71.88107.17
Key Statistics
Edit
Prev. Close
102.36
Open
101.45
Day's Range
100.9-102.4
52 wk Range
71.88-107.17
Volume
6.2M
Average Volume (3m)
8.28M
1-Year Change
31.72%
Book Value / Share
15.02
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
BSX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
117.14
Upside
+14.44%
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a high earnings multiple

Boston Scientific Corp News & Analysis

Show more

Boston Scientific Corp Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates in two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention portfolios; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, proprietary programming software, radiofrequency ablation, indirect decompression systems, and intraosseous nerve ablation and deep brain stimulation systems. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat, and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Boston Scientific Corp SWOT Analysis


Medtech Innovato
Boston Scientific's robust 17.61% revenue growth and strong financial health underscore its dominance in the medical technology sector, driven by innovative products
Strategic Expansion
Explore how the Axonics acquisition strengthens Boston Scientific's position in urology and pelvic health, potentially boosting revenue growth and market reach
Market Valuation
Analyst price targets range from $86 to $118, reflecting optimism about Boston Scientific's growth prospects and market position in the competitive healthcare industry
Future Growth Drivers
Delve into Boston Scientific's product pipeline, including the promising Watchman device, which could significantly expand the company's addressable market and drive long-term growth
Read full SWOT analysis

Boston Scientific Corp Earnings Call Summary for Q1/2025

  • Boston Scientific's Q1 2025 EPS of $0.75 and revenue of $4.66B beat forecasts, driving a 7.27% stock price increase to $101.96
  • Revenue grew 20.9% YoY, with organic growth of 18.2% exceeding guidance. WATCHMAN franchise and electrophysiology showed significant growth
  • Full-year 2025 guidance: 12-14% organic revenue growth, adjusted EPS $2.87-$2.94. Empower leadless pacemaker launch planned for H2 2025
  • Challenges include $200M tariff impact in 2025, potential 2026 tax rate increase, and pricing pressures in China despite expected growth
  • Strong financial health score of 3.05, with robust profitability (4.09) and price momentum (3.77) according to InvestingPro data
Last Updated: 04/23/2025, 09:42 PM
Read Full Transcript

Compare BSX to Peers and Sector

Metrics to compare
BSX
Peers
Sector
Relationship
P/E Ratio
74.5x−13.8x−0.5x
PEG Ratio
4.85−0.210.00
Price/Book
6.8x2.9x2.6x
Price / LTM Sales
8.6x3.9x3.0x
Upside (Analyst Target)
16.3%42.9%52.5%
Fair Value Upside
Unlock0.8%8.7%Unlock

Analyst Ratings

32 Buy
3 Hold
0 Sell
Ratings:
35 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 117.14
(+14.44% Upside)

Earnings

Latest Release
Apr 23, 2025
EPS / Forecast
0.75 / 0.67
Revenue / Forecast
4.66B / 4.57B
EPS Revisions
Last 90 days

BSX Income Statement

People Also Watch

300.68
UNH
-0.44%
253.77
AVGO
+1.51%
293.13
COR
-0.18%
378.72
HCA
+0.32%
335.40
APP
+3.30%

FAQ

What Is the Boston Scientific (BSX) Stock Price Today?

The Boston Scientific stock price today is 102.36

What Stock Exchange Does Boston Scientific Trade On?

Boston Scientific is listed and trades on the New York Stock Exchange stock exchange.

What Is the Stock Symbol for Boston Scientific?

The stock symbol for Boston Scientific is "BSX."

What Is the Boston Scientific Market Cap?

As of today, Boston Scientific market cap is 151.44B.

What Is Boston Scientific's Earnings Per Share (TTM)?

The Boston Scientific EPS (TTM) is 1.38.

When Is the Next Boston Scientific Earnings Date?

Boston Scientific will release its next earnings report on Jul 22, 2025.

From a Technical Analysis Perspective, Is BSX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Boston Scientific Stock Split?

Boston Scientific has split 2 times.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.